课题基金 / 基金详情

A Bioengineerable Self-adjuvating Nanoparticle for Antigen Delivery

A Bioengineerable Self-adjuvating Nanoparticle for Antigen Delivery
用于抗原递送的生物工程自辅助纳米颗粒
批准号:
8665391
负责人:
SHILADITYA DASSARMA
金额:
$7.68万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-05-25 至 2016-04-30

项目摘要

项目成果

SHILADITYA DASSARMA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A unique vaccine platform employs novel bioengineerable nanoparticles, Haloarchaeal gas vesicles (HGVs), as an adjuvant and antigen delivery system that is inexpensive, effective, and shelf-stable (requiring no refrigeration). When administered to animals, HGV nanoparticles with surface-displayed antigens produce strong long-lived immune responses. In previous work, antigens from bacterial and viral pathogens were expressed as a fusion to one of the HGV protein components and in all cases the recombinant HGVs were highly immunogenic in mice. We plan to test the effectiveness of HGVs as a vaccine vehicle against Salmonella enterica serovar Typhi, the causative agent of typhoid fever. These human pathogens remain important causes of morbidity and mortality in many countries as a result of poor sanitation, and water and food contaminated by human fecal waste. Our goal is to progress toward the development of a safe and inexpensive oral vaccine against invasive Salmonella disease that can be used in both the developing and developed world. We propose to: (a) produce multiple Salmonella protective antigens displayed on HGV nanoparticles; and (b) deliver the bioengineered HGV-vaccine antigen nanoparticles and determine their protective efficacy in a mouse model. We will also perform more in-depth immunological analyses and test protection using combinations of HGV formulations. These studies will lay the foundation for subsequent evaluation of this approach in humans as well as customize the system for prevention of other diseases. The development of a safe, oral adjuvant and vaccine delivery vehicle which is inexpensive, effective, and shelf-stable should lead to a global revolution in the prevention of infectious diseases.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/vaccines3030686
发表时间: 2015-09-07
期刊: Vaccines
影响因子: 7.8
作者: [DasSarma S, DasSarma P]
通讯作者: DasSarma P
DOI: 10.1016/j.mib.2015.05.009
发表时间: 2015-06
期刊: Current opinion in microbiology
影响因子: 5.4
作者: [DasSarma S, DasSarma P]
通讯作者: DasSarma P
DOI: 10.1016/j.provac.2015.05.003
发表时间: 2015
期刊: Procedia in vaccinology
影响因子: --
作者: [DasSarma P, Negi VD, Balakrishnan A, Kim JM, Karan R, Chakravortty D, DasSarma S]
通讯作者: DasSarma S
DOI: 10.1186/1472-6750-13-112
发表时间: 2013-12-21
期刊: BMC biotechnology
影响因子: 3.5
作者: [DasSarma S, Karan R, DasSarma P, Barnes S, Ekulona F, Smith B]
通讯作者: Smith B
6
    A Bioengineerable Self-adjuvating Nanoparticle for Antigen Delivery
    • 批准号:
      8570051
    • 项目类别:
    • 资助金额:
      $7.68万
    • 财政年份:
      2013
    • 负责人:
      SHILADITYA DASSARMA
    • 依托单位:
    HIV ANTIGEN DISPLAY USING RECOMBINANT FLOATING VESICLES
    REGULATION OF GENE EXPRESSION IN HALOBACTERIUM HALOBIUM
    REGULATION OF GENE EXPRESSION IN HALOBACTERIUM HALOBIUM
    海外基金